{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:49:15Z","timestamp":1777495755748,"version":"3.51.4"},"reference-count":34,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Initial therapy for low-risk patients typically involves potent antiresorptive agents such as bisphosphonates or denosumab to reduce bone resorption and fracture risk. For high-risk patients, bone anabolic agents like teriparatide or romosozumab may be preferred to stimulate bone formation, rapidly increase bone mass and enhance fracture prevention. Effective transitions between therapies are essential to sustain skeletal benefits. This review explores evidence-based strategies for sequential osteoporosis treatment.<\/jats:p>","DOI":"10.61409\/v03250171","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:44:26Z","timestamp":1761137066000},"page":"1-9","source":"Crossref","is-referenced-by-count":1,"title":["Sequence treatment of postmenopausal osteoporosis"],"prefix":"10.61409","author":[{"given":"Pia","family":"Eiken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane Dahl","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Pernille","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens-Erik Beck","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bente L.","family":"Langdahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Johansson H, Siggeirsd\u00f3ttir K, Harvey NC, et al. Imminent risk of fracture after fracture. Osteoporos Int. 2017;28(3)75-780. https:\/\/doi.org\/10.1007\/s00198-016-3868-0","DOI":"10.1007\/s00198-016-3868-0"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Balasubramanian A, Zhang J, Chen L, et al. Risk of subsequent fracture after prior fracture among older women. Osteoporos Int. 2019;30(1):79-92. https:\/\/doi.org\/10.1007\/s00198-018-4732-1","DOI":"10.1007\/s00198-018-4732-1"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Cosman F, Lewiecki EM, Eastell R, et al. Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024. J Bone Miner Res. 2024;39(10):1393-1405. https:\/\/doi.org\/10.1093\/jbmr\/zjae119","DOI":"10.1093\/jbmr\/zjae119"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Cosman F, Langdahl B, Leder BZ. Treatment sequence for osteoporosis. Endocr Pract. 2024;30(5):490-496. https:\/\/doi.org\/10.1016\/j.eprac.2024.01.014","DOI":"10.1016\/j.eprac.2024.01.014"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Langdahl BL. Overview of treatment approaches to osteoporosis. Br J Pharmacol. 2021;178(9):1891-1906. https:\/\/doi.org\/10.1111\/bph.15024","DOI":"10.1111\/bph.15024"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Black DM, Bauer DC, Vittinghoff E, et al. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. Lancet Diabetes Endocrinol. 2020;8(8):672-682. https:\/\/doi.org\/10.1016\/S2213-8587(20)30159-5","DOI":"10.1016\/S2213-8587(20)30159-5"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"H\u00e4ndel MN, Cardoso I, von B\u00fclow C, et al. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ. 2023;381:e068033. https:\/\/doi.org\/10.1136\/bmj-2021-068033","DOI":"10.1136\/bmj-2021-068033"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Hadji P, Zanchetta JR, Russo L, et al. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int. 2012;23(8):2141-2150. https:\/\/doi.org\/10.1007\/s00198-011-1856-y","DOI":"10.1007\/s00198-011-1856-y"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391(10117):230-240. https:\/\/doi.org\/10.1016\/S0140-6736(17)32137-2","DOI":"10.1016\/S0140-6736(17)32137-2"},{"issue":"15","key":"ref9","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417-1427.","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1708322","DOI":"10.1056\/NEJMoa1708322"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Saag KG, Zanchetta JR, Devogelaer J, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346-3355. https:\/\/doi.org\/10.1002\/art.24879","DOI":"10.1002\/art.24879"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015;386(9999):1147-1155. https:\/\/doi.org\/10.1016\/S0140-6736(15)61120-5","DOI":"10.1016\/S0140-6736(15)61120-5"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Cosman F, Kendler DL, Langdahl BL, et al. Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int. 2022;33(6):1243-1256. https:\/\/doi.org\/10.1007\/s00198-021-06174-0","DOI":"10.1007\/s00198-021-06174-0"},{"issue":"12","key":"ref14","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer J, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189-1199.","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa030897","DOI":"10.1056\/NEJMoa030897"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27(2):243-254. https:\/\/doi.org\/10.1002\/jbmr.1494","DOI":"10.1002\/jbmr.1494"},{"key":"ref17","unstructured":"Eiken PA, Abrahamsen B. Osteoporosebehandling kan pauseres efter individuel vurdering. Ugeskr L\u00e6ger. 2017;179:V05160327. https:\/\/ugeskriftet.dk\/videnskab\/osteoporosebehandling-kan-pauseres-efter-individuel-vurdering"},{"issue":"24","key":"ref18","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927-2938.","journal-title":"JAMA"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"https:\/\/doi.org\/10.1001\/jama.296.24.2927","DOI":"10.1001\/jama.296.24.2927"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513-523. https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","DOI":"10.1016\/S2213-8587(17)30138-9"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Watts NB. What to do when denosumab is stopped? JAMA Netw Open. 2024;7(11):e2443879. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.43879","DOI":"10.1001\/jamanetworkopen.2024.43879"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M, et al. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 2017;105:11-17. https:\/\/doi.org\/10.1016\/j.bone.2017.08.003","DOI":"10.1016\/j.bone.2017.08.003"},{"key":"ref23","unstructured":"Eiken PA. Roloxifens langtidseffekter p\u00e5 knoglerne. Ugeskr L\u00e6ger. 2008;170(4):224-226. https:\/\/ugeskriftet.dk\/videnskab\/raloxifens-langtidseffekter-pa-knoglerne"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res. 2005;20(9):1514-1524. https:\/\/doi.org\/10.1359\/JBMR.050509","DOI":"10.1359\/JBMR.050509"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Cosman F, Lewiecki EM, Ebeling PR, et al. T-score as an indicator of fracture risk during treatment with romosozumab or alendronate in the ARCH trial. J Bone Miner Res. 2020;35(7):1333-1342. https:\/\/doi.org\/10.1002\/jbmr.3996","DOI":"10.1002\/jbmr.3996"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, et al. One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res. 2019;34(3):419-428. https:\/\/doi.org\/10.1002\/jbmr.3622","DOI":"10.1002\/jbmr.3622"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-1441. https:\/\/doi.org\/10.1056\/NEJM200105103441904","DOI":"10.1056\/NEJM200105103441904"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004;164(18):2024-2030. https:\/\/doi.org\/10.1001\/archinte.164.18.2024","DOI":"10.1001\/archinte.164.18.2024"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Cosman F, Nieves JW, Roimisher C, et al. Administration of teriparatide for four years cyclically compared to two years daily in treatment na\u00efve and alendronate treated women. Bone. 2019;120:246-253. https:\/\/doi.org\/10.1016\/j.bone.2018.10.020","DOI":"10.1016\/j.bone.2018.10.020"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390(10102):1585-1594. https:\/\/doi.org\/10.1016\/S0140-6736(17)31613-6","DOI":"10.1016\/S0140-6736(17)31613-6"},{"issue":"8","key":"ref31","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","unstructured":"Miller PD, Pannacciulli N, Brown JP, et al. Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab. 2016;101(8):3163-3170.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"https:\/\/doi.org\/10.1210\/jc.2016-1801","DOI":"10.1210\/jc.2016-1801"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Eiken P, Vestergaard P. Treatment of osteoporosis after alendronate or risedronate. Osteoporos Int. 2016;27(1):1-12. https:\/\/doi.org\/10.1007\/s00198-015-3334-4","DOI":"10.1007\/s00198-015-3334-4"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:49:12Z","timestamp":1761223752000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V03250171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":34,"URL":"https:\/\/doi.org\/10.61409\/v03250171","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"value":"0041-5782","type":"print"},{"value":"1603-6824","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]}}}